MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease

Clinica Chimica Acta

Volumn 411, Issue 9-10, 2010, Pages 719-724

  Gai, Xiaobo ^a   Zhang, Zhigang ^a   Liang, Yonggang ^a   Chen, Zheming ^a   Yang, Xiangyue ^a   Hou, Jiake ^a   Lan, Xiaopeng ^a   Zheng, Weixing ^a   Hou, Jianping ^a   Huang, Mingfang ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Atrial fibrillation; Gene polymorphism; Hypertensive heart disease; MMP 2; TIMP 2

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AGED; ARTICLE; CHINESE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART LEFT VENTRICLE MASS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUALITY CONTROL;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CHINA; FEMALE; GENE FREQUENCY; GENOTYPE; HEART ATRIA; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77950459505     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.02.002     Document Type: Article

References (40)

1. Neuberger H.R., Schotten U., Blaauw Y., et al. Chronic atrial dilation, electrical remodeling, and atrial fibrillation in the goat. J Am Coll Cardiol 2006, 47:644-653.
2. Sridhar A., Nishijima Y., Terentyev D., et al. Chronic heart failure and the substrate for atrial fibrillation. Cardiovasc Res 2009, 84:387-395.
3. Anne W., Willems R., Holemans P., et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 2007, 43:148-158.
4. Cha T.J., Ehrlich J.R., Zhang L., et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 2004, 109:412-418.
5. Polyakova V., Miyagawa S., Szalay Z., Risteli J., Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008, 12:189-208.
6. Hoyano M, Ito M, Kimura S, et al. Inducibility of atrial fibrillation depends not on inflammation but on atrial structural remodeling in rat experimental autoimmune myocarditis. Cardiovasc Pathol in press.
7. Lin C.S., Pan C.H. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 2008, 65:1489-1508.
8. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
9. Xu J., Cui G., Esmailian F., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004, 109:363-368.
10. Gramley F., Lorenzen J., Plisiene J., et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18:1076-1082.
11. Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001, 276:7549-7558.
12. Yu C., Zhou Y., Miao X., Xiong P., Tan W., Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004, 64:7622-7628.
13. Kato K., Oguri M., Hibino T., et al. Genetic factors for lone atrial fibrillation. Int J Mol Med 2007, 19:933-939.
14. De Clerck Y.A., Darville M.I., Eeckhout Y., Rousseau G.G. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 1994, 139:185-191.
15. Hirano K., Sakamoto T., Uchida Y., et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001, 18:748-752.
16. Zhou Y., Yu C., Miao X., et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004, 25:399-404.
17. Yi Y.C., Chen M.K., Chen L.Y., et al. Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer. Clin Chim Acta 2009, 409:127-131.
18. O-Charoenrat P., Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 2006, 42:257-267.
19. Lin T.H., Chiu H.C., Lee Y.T., et al. The C-allele of tissue inhibitor of metalloproteinases 2 is associated with increased magnitude of QT dispersion prolongation in elderly Chinese-4-year follow-up study. Clin Chim Acta 2007, 386:87-93.
20. Verdecchia P., Reboldi G., Gattobigio R., et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003, 41:218-223.
21. Kistler P.M., Sanders P., Dodic M., et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006, 27:3045-3056.
22. Choisy S.C., Arberry L.A., Hancox J.C., James A.F. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension 2007, 49:498-505.
23. Liu F., Levin M.D., Petrenko N.B., et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol 2008, 45:715-723.
24. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
25. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
26. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991, 114:345-352.
27. Gai X., Lan X., Luo Z., et al. Association of MMP-9 gene polymorphisms with atrial fibrillation in hypertensive heart disease patients. Clin Chim Acta 2009, 408:105-109.
28. Huang M., Gai X., Yang X., et al. Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. Clin Chem Lab Med 2009, 47:32-37.
29. Gauderman W.J. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 2002, 155:478-484.
30. Fox C.S., Parise H., D'Agostino R.B., et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004, 291:2851-2855.
31. Arnar D.O., Thorvaldsson S., Manolio T.A., et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006, 27:708-712.
32. Chen Y.H., Xu S.J., Bendahhou S., et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003, 299:251-254.
33. Yang Y., Xia M., Jin Q., et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet 2004, 75:899-905.
34. Gudbjartsson D.F., Arnar D.O., Helgadottir A., et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007, 448:353-357.
35. Benjamin E.J., Rice K.M., Arking D.E., et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009, 41:879-881.
36. Tsai C.T., Lai L.P., Lin J.L., et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004, 109:1640-1646.
37. Ravn L.S., Benn M., Nordestgaard B.G., et al. Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenet Genomics 2008, 18:525-533.
38. Marcus G.M., Whooley M.A., Glidden D.V., Pawlikowska L., Zaroff J.G., Olgin J.E. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008, 155:303-309.
39. Matsusaka H., Ide T., Matsushima S., et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006, 47:711-717.
40. Arenas I.A., Xu Y., Lopez-Jaramillo P., Davidge S.T. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol 2004, 286:C779-C784.